Marion Pain Center, LLC

Marion Pain Center, LLC was paid $5.90M by Medicaid between Jan 2018 and Dec 2024, across 110 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 21% of everything it billed.

Compared with peers

Next to other Addiction (Substance Use Disorder) Counselor providers in Ohio

Rank by total paid#26 of 540

Median peer was paid$25K

This provider vs. median241×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	79,980	$823K
2019	71,451	$948K
2020	53,705	$796K
2021	29,630	$778K
2022	27,830	$886K
2023	23,716	$906K
2024incomplete	22,601	$767K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	21%	8,559	7,780	$1.21M
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	16%	33,329	30,265	$961K
93923		9.8%	8,532	4,211	$579K
01992		7.8%	10,820	8,385	$461K
64635		4.0%	2,427	1,871	$239K
95924		3.9%	4,488	4,148	$230K
64636		3.1%	2,364	1,790	$183K
64493		2.4%	2,099	1,630	$143K
80305		2.3%	19,313	17,364	$139K
95923		2.0%	3,694	3,431	$117K
62323		1.6%	847	664	$96K
80346		1.2%	3,889	3,538	$73K

98 more codes

64494		1.2%	2,293	$70K
27096		1.1%	427	$64K
64495		<1%	2,228	$59K
80362		<1%	7,622	$51K
80361		<1%	3,889	$50K
99203	Doctor's office visit, new patient (routine)	<1%	1,233	$49K
99454		<1%	1,392	$45K
80320		<1%	3,889	$41K
80368		<1%	3,889	$40K
83992		<1%	3,893	$40K
99457		<1%	1,385	$35K
80360		<1%	3,889	$35K
80345		<1%	3,889	$35K
80324		<1%	3,889	$35K
90832	Psychotherapy session, about 30 minutes	<1%	1,038	$34K
80366		<1%	3,889	$33K
80355		<1%	3,889	$33K
80367		<1%	3,889	$33K
80333		<1%	3,889	$33K
80337		<1%	3,888	$33K
80372		<1%	3,889	$33K
80373		<1%	3,938	$33K
80369		<1%	3,889	$33K
80323		<1%	3,889	$31K
80354		<1%	3,889	$28K
80365		<1%	3,889	$28K
80356		<1%	3,889	$28K
80348		<1%	3,889	$28K
80371		<1%	3,889	$28K
80353		<1%	3,889	$28K
80359		<1%	3,906	$28K
80350		<1%	3,889	$28K
80349		<1%	3,861	$28K
80358		<1%	3,853	$28K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	3,411	$24K
J1040	Injection, methylprednisolone acetate, 80 mg	<1%	3,477	$23K
77002		<1%	1,532	$23K
93040		<1%	4,430	$20K
64490		<1%	224	$16K
99401		<1%	1,400	$14K
J1030	Injection, methylprednisolone acetate, 40 mg	<1%	2,573	$10K
64491		<1%	247	$8K
64483		<1%	109	$8K
J2704	Injection, propofol, 10 mg	<1%	9,736	$6K
64484		<1%	97	$6K
64492		<1%	199	$5K
64633		<1%	53	$5K
01940		<1%	134	$5K
64634		<1%	52	$5K
64450		<1%	117	$5K
96521		<1%	55	$4K
77003		<1%	1,075	$3K
J1010	Injection, methylprednisolone acetate, 1 mg	<1%	884	$3K
J3490	Unclassified drugs	<1%	973	$3K
99406		<1%	558	$2K
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	<1%	55	$2K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	279	$2K
99214	Doctor's office visit, returning patient (more involved)	<1%	32	$1K
64445		<1%	17	$1K
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	5,829	$1K
99453		<1%	120	$1K
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	55	$974.96
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	6,089	$857.31
80306		<1%	365	$749.64
99072		<1%	7,841	$526.13
99497		<1%	346	$496.32
01991		<1%	23	$415.35
36415	Collection of venous blood by venipuncture	<1%	55	$233.37
A4209	Syringe with needle, sterile 5 cc or greater, each	<1%	2,170	$183.16
82962		<1%	55	$178.70
94060		<1%	14	$131.84
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	69	$75.10
A4649	Surgical supply; miscellaneous	<1%	1,562	$56.96
A4208	Syringe with needle, sterile 3 cc, each	<1%	1,499	$49.43
J0665	Injection, bupivicaine, not otherwise specified, 0.5 mg	<1%	412	$43.17
94760		<1%	4,008	$30.63
J1817	Insulin for administration through dme (i.e., insulin pump) per 50 units	<1%	55	$19.76
J7050	Infusion, normal saline solution, 250 cc	<1%	24	$7.59
G0444	Annual depression screening, 5 to 15 minutes	<1%	303	$0.76
G8482	Influenza immunization administered or previously received	0%	2,371	$0.00
4040F		0%	3,575	$0.00
G8783	Normal blood pressure reading documented, follow-up not required	0%	1,033	$0.00
4004F		0%	1,860	$0.00
G9744	Patient not eligible due to active diagnosis of hypertension	0%	1,381	$0.00
G8753	Most recent systolic blood pressure >= 140 mmhg	0%	1,682	$0.00
99408		0%	102	$0.00
G8417	Bmi is documented above normal parameters and a follow-up plan is documented	0%	2,820	$0.00
G8427	Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications	0%	3,264	$0.00
G0446	Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes	0%	279	$0.00
G8752	Most recent systolic blood pressure < 140 mmhg	0%	1,642	$0.00
G8484	Influenza immunization was not administered, reason not given	0%	1,001	$0.00
G0247	Routine foot care by a physician of a diabetic patient with diabetic sensory neuropathy resulting in a loss of protective sensation (lops) to include, the local care of superficial wounds (i.e. superficial to muscle and fascia) and at least the following if present: (1) local care of superficial wounds, (2) debridement of corns and calluses, and (3) trimming and debridement of nails	0%	173	$0.00
G8754	Most recent diastolic blood pressure < 90 mmhg	0%	1,882	$0.00
G8755	Most recent diastolic blood pressure >= 90 mmhg	0%	1,379	$0.00
G8420	Bmi is documented within normal parameters and no follow-up plan is required	0%	212	$0.00
G8950	Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented	0%	879	$0.00
1036F		0%	1,495	$0.00
G0245	Initial physician evaluation and management of a diabetic patient with diabetic sensory neuropathy resulting in a loss of protective sensation (lops) which must include: (1) the diagnosis of lops, (2) a patient history, (3) a physical examination that consists of at least the following elements: (a) visual inspection of the forefoot, hindfoot and toe web spaces, (b) evaluation of a protective sensation, (c) evaluation of foot structure and biomechanics, (d) evaluation of vascular status and skin integrity, and (e) evaluation and recommendation of footwear and (4) patient education	0%	172	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialKATABAY, ADIL (PHYSICIAN)

Same official

Other billing entities under KATABAY, ADIL

Full network →

Provider	Location	Paid
Marion Pain Center, LLC	Marion, OH	$715.80

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.